TIGIT inhibitor M6223 as monotherapy or in combination with bintrafusp alfa in patients with advanced solid tumors: a first-in-human, phase 1, dose-escalation trial by Wei Gao, Ping Hu, Aung Naing, Meredith McKean, Anthony Tolcher, Lillian L Siu, Keyvan Tadjalli-Mehr, Anja Victor, Emilia Richter, Marco A F Nogueira Filho, Thomas Kitzing, Stephan Gleicher, Daniel Holland

“…RDEs were 1600 mg every 2 weeks or 2400 mg every 3 weeks for M6223 monotherapy and 1600+1200 mg every 2 weeks for M6223+BA.Conclusions M6223±BA had a manageable safety profile, with RDEs defined for both monotherapy and combination therapy. Further evaluation of M6223 is ongoing in combination with the PD-L1 inhibitor avelumab in patients with advanced urothelial carcinoma (JAVELIN Bladder Medley; NCT05327530).Trial registration number NCT04457778.…”
Get full text

Integrating rapamycin with novel PI3K/Akt/mTOR inhibitor microRNAs on NOTCH1-driven T-cell acute lymphoblastic leukemia (T-ALL) by Fateme Arjmand, Samaneh Shojaei, Mitra Khalili, Hossein Dinmohammadi, Behzad Poopak, Samira Mohammadi-Yeganeh, Yousef Mortazavi

“…Furthermore, in order to evaluate the potential of combination therapy involving miRNAs and rapamycin, apoptosis and cell cycle assays were carried out. …”
Get full text

PD-1 cis-targeted IL-2v in combination with radiotherapy inhibits lung cancer growth and remodels the immune microenvironment by Pedro J Romero, Sara Labiano, Gregory Verdeil, Christian Klein, Pablo Umana, Tania Wyss, Christine Trumpfheller, Marie-Catherine Vozenin, Céline Godfroid, Jackeline Romero, Vincent Roh, Genrich V Tolstonog, Chia-Hsien Chuang, Andrea Kelemen, Laura Codarri Deak

“…Importantly, this combination therapy was devoid of measurable toxicity. It induced remodeling of the immune contexture through the increase of CD8+ T and natural killer (NK) cells. …”
Get full text

Antimycobacterial Activity, Synergism, and Mechanism of Action Evaluation of Novel Polycyclic Amines against Mycobacterium tuberculosis by Erika Kapp, Jacques Joubert, Samantha L. Sampson, Digby F. Warner, Ronnett Seldon, Audrey Jordaan, Margaretha de Vos, Rajan Sharma, Sarel F. Malan

“…To this end, antimycobacterial activity, mechanism of action, and synergism in combination therapy were investigated for a series of polycyclic amine derivatives. …”
Get full text

A Multifunctional MIL-101-NH2(Fe) Nanoplatform for Synergistic Melanoma Therapy by Shang J, Chen Y, Wang F, Yang J, Li Y, Yang L, Liu X, Zhong Z, Yue C, Zhou M

“…Jinlu Shang,1,2,* Yongjun Chen,2,* Fangliang Wang,3,* Jing Yang,2 Yi Li,4 Liuxuan Yang,2 Xiuqiong Liu,1 Zhirong Zhong,5 Chaochi Yue,6 Meiling Zhou2 1Department of Pharmacy, West China Hospital Sichuan University Jintang Hospital, Chengdu, Sichuan, 610400, People’s Republic of China; 2Department of Pharmacy, The Affiliated Hospital, Southwest Medical University, Luzhou, Sichuan, 646000, People’s Republic of China; 3Chongqing Key Laboratory for Pharmaceutical Metabolism Research, Chongqing Pharmacodynamic Evaluation Engineering Technology Research Center, College of Pharmacy Chongqing Medical University, Chongqing, 400016, People’s Republic of China; 4Department of Nuclear Medicine, The Affiliated Hospital, Southwest Medical University, Luzhou, Sichuan, 646000, People’s Republic of China; 5Department of Pharmaceutical Sciences, School of Pharmacy, Southwest Medical University, Luzhou, Sichuan, 646000, People’s Republic of China; 6Department of Traditional Chinese Medicine, The Affiliated Hospital, Southwest Medical University, Luzhou, Sichuan, 646000, People’s Republic of China*These authors contributed equally to this workCorrespondence: Meiling Zhou; Chaochi Yue, Email meilzhou@163.com; yuechaochi18@swmu.edu.cnBackground: Melanoma is an aggressive form of skin cancer, and single-modality treatments often fail to prevent tumor recurrence and metastasis. Combination therapy has emerged as an effective approach to improve treatment outcomes.Methods: In this study, we developed a multifunctional nanoplatform, MIL@DOX@ICG, utilizing MIL-101-NH2(Fe) as a carrier to co-deliver the chemotherapeutic agent doxorubicin (DOX) and the photosensitizer indocyanine green (ICG). …”
Get full text

The Effects of Statin Dose, Lipophilicity, and Combination of Statins plus Ezetimibe on Circulating Oxidized Low-Density Lipoprotein Levels: A Systematic Review and Meta-Analysis o... by Tannaz Jamialahmadi, Fatemeh Baratzadeh, Željko Reiner, Luis E. Simental-Mendía, Suowen Xu, Andrey V. Susekov, Raul D. Santos, Amirhossein Sahebkar

“…There was no difference concerning ox-LDL concentration between treatments with hydrophilic and lipophilic statins (SMD: -0.129, 95% CI: -0.330, -0.071, p=0.206; I2: 45.3%), but there was a significant reduction in circulating concentrations of ox-LDL associated with statin plus ezetimibe combination therapy when compared with statin monotherapy (SMD: -0.220, 95% CI: -0.369, -0.071, p=0.004; I2: 0%). …”
Get full text

Drug-drug interaction between ensitrelvir and tacrolimus in a patient undergoing treatment for COVID-19: a case report by Yuki Miyata, Ryo Yamaguchi, Takehito Yamamoto, Toshiyuki Kishida, Kazuhiko Ikeuchi, Hiroaki Harada, Takeya Tsutsumi, Keishi Fujio, Tappei Takada

“…Considering persistent COVID-19, we initiated combination therapy with remdesivir and ensitrelvir (day 0). …”
Get full text

Clinical Characteristics and Optimization of Empirical Antimicrobial Therapy for Febrile Neutropenia in Patients With Hematologic Malignancies by Cui Y, Liu X, Feng S

“…In cases of pneumonia, shock, or suspected carbapenem-resistant infections, combination therapy, tigecycline, and newer antibiotics like ceftazidime/avibactam (CAZ/AVI) are often used. …”
Get full text

CD4 T cell depletion increases memory differentiation of endogenous and CAR T cells and enhances the efficacy of Super2 and IL-33-armored CAR T cells against solid tumors by Chrystal Paulos, Mary Jo Turk, Megen C Wittling, Yina H Huang, Asmaa O Mohamed, David Tyler Boone, Shannon L Ferry, Melanie C Peck, Alicia M Santos, Haille E Soderholm

“…CD4 depletion and S233-armored CAR T cell combination therapy synergized to increase endogenous memory T cells.Conclusions Unarmored TRP-1-specific or NKG2D CAR T cells have intrinsic stem-like properties and differentiate into memory T cell subsets but are non-protective against primary or secondary tumors. …”
Get full text

Poor efficacy of the combination of clarithromycin, amikacin, and cefoxitin against Mycobacterium abscessus in the hollow fiber infection model by Etienne Vignaud, Sylvain Goutelle, Charlotte Genestet, Jérôme Guitton, Sabine Cohen, Chloé Bourg, Aurore Durand, Laura Lebouteiller, Albin Bernard, Caroline Richet, Oana Dumitrescu, Elisabeth Hodille

“…Abstract Background Mycobacterium abscessus (MABS) causes difficult-to-treat pulmonary and extra-pulmonary infections. A combination therapy comprising amikacin, cefoxitin, and a macrolide agent is recommended, but its antimicrobial activity and clinical efficacy is uncertain. …”
Get full text

CD4 T cell dynamics shape the immune response to combination oncolytic herpes virus and BRAF inhibitor therapy for melanoma by Victoria Jennings, Kevin Harrington, Hardev Pandha, Alan Melcher, Adel Samson, Fiona Errington-Mais, Victoria Roulstone, Eva Crespo-Rodriguez, Galabina Bozhanova, Shane Foo, Emmanuel C Patin, Martin McLaughlin, Malin Pedersen, Richard Vile, Joan Kyula, Jehanne Hassan, Lizzie Appleton, Charleen ML Chan Wah Hak, Gabby Baker, Edward Armstrong, Matthew Chiu, Masahiro Ono

“…This immune data was used to inform the selection of ICI for triple combination therapy, the effects of which were then further characterized using transcriptomics.Results Adding BRAFi treatment to HSV improved anti-tumor effects in vivo but not in vitro. …”
Get full text

Study Protocol of the Korean EGFR Registry: A Multicenter Prospective and Retrospective Cohort Study in Nonsmall Cell Lung Cancer Patients With EGFR Mutation by Chang Dong Yeo, Dong Won Park, Seong Hoon Yoon, Eun Young Kim, Jeong Eun Lee, Shin Yup Lee, Chang‐Min Choi, In‐Jae Oh, Do Jin Kim, Jeong Seon Ryu, Jae Cheol Lee, Young‐Chul Kim, Tae Won Jang, Kye Young Lee, Seung Hun Jang, Seung Joon Kim, for the Korean EGFR Registry Investigators

“…The primary endpoint is disease‐free survival in patients who have undergone radical therapy (surgery and radiotherapy) or progression‐free survival in those receiving targeted therapy (first, second, and subsequent lines), chemotherapy (first and subsequent lines), combination therapy, and palliative/maintenance therapy according to stages of EGFR‐mutated NSCLC. …”
Get full text

Optimal radiation dose to induce an abscopal effect by combining carbon-ion radiotherapy and anti-CTLA4 antibody by Liqiu Ma, Yang Li, Yoshimitsu Sakamoto, Lin Xie, Saaya Suzuki, Yukari Yoshida, Li Sui, Gang Guo, Jialing Wen, Wangcai Ren, Kazuhiro Kakimi, Kensuke Osada, Akihisa Takahashi, Takashi Shimokawa

“…Conclusion: Our findings suggest that there is an optimal dose range for the abscopal effect generated with the CIRT combined with anti-CTLA4 antibody, and it highlights a new opportunity for increased induction efficiency of the abscopal effect of combination therapy.…”
Get full text

The role of artificial intelligence and machine learning in predicting and combating antimicrobial resistance by Hazrat Bilal, Muhammad Nadeem Khan, Sabir Khan, Muhammad Shafiq, Wenjie Fang, Rahat Ullah Khan, Mujeeb Ur Rahman, Xiaohui Li, Qiao-Li Lv, Bin Xu

“…These models can provide insights into the discovery of novel antimicrobials, the repurposing of existing drugs, and combination therapy through the analysis of their molecular structures. …”
Get full text

Engineering dual-driven pro-angiogenic nanozyme based on porous silicon for synergistic acceleration of burn infected wound healing by Wei Duan, Yue Gao, Ruru Xu, Sheng Huang, Xueqian Xia, Jingwen Zhao, Longhuan Zeng, Qiaolin Wei, Jia-Wei Shen, Jianmin Wu, Yongke Zheng

“…After exposure to 808 nm NIR laser, Pt@PSi-based photothermal and nano-catalytic combined therapy can achieve more than 95 % bacterial inhibition in vitro. …”
Get full text

Tasquinimod suppresses tumor cell growth and bone resorption by targeting immunosuppressive myeloid cells and inhibiting c-MYC expression in multiple myeloma by Marie Törngren, Rong Fan, Eline Menu, Helena Eriksson, Karin Vanderkerken, Andrew Chantry, Hatice Satilmis, Niels Vandewalle, Emma Verheye, Philip Vlummens, Anke Maes, Catharina Muylaert, Elke De Bruyne, Holly Evans, Nathan De Beule, Dirk Hose, Ken Maes, Karine Breckpot, Kim De Veirman

“…Tasquinimod significantly reduced the tumor load and increased the trabecular bone volume, which resulted in prolonged overall survival of MM-bearing mice in vivo.Conclusion Our study provides novel insights in the dual therapeutic effects of the immunomodulator tasquinimod and fosters its evaluation in combination therapy trials for MM patients.…”
Get full text

Ibrutinib disrupts blood-tumor barrier integrity and prolongs survival in rodent glioma model by Sanghee Lim, Minhye Kwak, Jeonghan Kang, Melissa Cesaire, Kayen Tang, Robert W. Robey, William J. E. Frye, Baktiar Karim, Donna Butcher, Martin J. Lizak, Mahalia Dalmage, Brandon Foster, Nicholas Nuechterlein, Charles Eberhart, Patrick J. Cimino, Michael M. Gottesman, Sadhana Jackson

“…Finally, Ibrutinib, combined with doxil, prolonged median survival in rodent glioma models (27 vs. 16 days, p < 0.0001) with brain imaging showing a − 53% versus − 75% volume change with doxil alone versus combination therapy (p < 0.05). These findings indicate ibrutinib’s ability to increase brain endothelial permeability via junctional disruption and efflux inhibition, to increase BTB drug entry and prolong rodent glioma model survival. …”
Get full text

Targeting NANOS1 in triple-negative breast cancer: synergistic effects of digoxin and PD-1 inhibitors in modulating the tumor immune microenvironment by Tangyi Wang, Yadian Lei, Jingwei Sun, Li Wang, Yuxin Lin, Zhijing Wu, Shoude Zhang, Chengzhu Cao, Chengzhu Cao, Chengzhu Cao, Haiyan Wang, Haiyan Wang, Haiyan Wang

“…Overall, this study identifies NANOS1 as a new target for TNBC therapy and suggests a combination therapy approach that could enhance immunotherapy effectiveness and improve patient outcomes.…”
Get full text

Diagnosis and Treatment of Gastroesophageal Reflux Disease (Clinical Guidelines of the Russian Gastroenterological Association, Russian Scientific Medical Society of Internal Medic... by V. T. Ivashkin, A. S. Trukhmanov, I. V. Maev, O. M. Drapkina, M. A. Livzan, A. I. Martynov, T. L. Lapina, A. V. Paraskevova, D. N. Andreev, O. P. Alexeeva, S. A. Alekseenko, A. Yu. Baranovsky, O. V. Zayratyants, O. Yu. Zolnikova, O. B. Dronova, I. L. Kliaritskaia, N. V. Korochanskaya, Yu. A. Kucheryavyy, S. N. Mammaev, M. F. Osipenko, S. S. Pirogov, E. A. Poluektova, D. E. Rumyantseva, R. G. Sayfutdinov, O. A. Storonova, Yu. P. Uspenskiy, I. B. Khlynov, V. V. Tsukanov, A. A. Sheptulin

“…PPIs are the drugs of choice in the treatment of both symptoms of gastroesophageal reflux disease and existing erosive esophagitis. Combination therapy Rebamipide with PPIs increases the effectiveness of relief of GERD symptoms, as well as reduces the frequency of relapses.Conclusion. …”
Get full text

ROR1 CAR-T cells and ferroptosis inducers orchestrate tumor ferroptosis via PC-PUFA2 by Dan Li, Wenjie Zhang, Ruiheng Wang, Shufeng Xie, Yixin Wang, Wanxin Guo, Zixuan Huang, Chaoqun Lu, Liang Shan, Han Liu, Lifang Ma, Xumin Hou, Zhenshu Xu, Jiayi Wang

“…Finally, tumor-bearing mice were used to validate the in vivo efficacy of the combination therapy strategy. Results Tumor cells treated with ferroptosis inducers showed increased sensitivity to Interferon gamma (IFN-γ) secreted by ROR1 CAR-T cells. …”
Get full text